Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENDP Endo International		$0.45	$0.28 ▼ $7.07	$141K	1.15	28.19 million shs	9,967 shs
MDGL Madrigal Pharmaceuticals	$315.46 +0.3%	$288.60	$200.63 ▼ $377.46	$6.99B	-1.05	358,537 shs	163,873 shs
SUPN Supernus Pharmaceuticals	$33.12 -0.1%	$32.26	$27.05 ▼ $40.28	$1.86B	0.7	487,537 shs	461,128 shs
TGTX TG Therapeutics	$37.08 -1.6%	$36.05	$16.65 ▼ $46.48	$5.98B	1.91	2.88 million shs	957,478 shs
YMAB Y-mAbs Therapeutics	$4.36 -3.5%	$4.48	$3.55 ▼ $16.11	$204.68M	0.51	295,481 shs	111,067 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENDP Endo International	0.00%	0.00%	0.00%	0.00%	0.00%
MDGL Madrigal Pharmaceuticals	+0.26%	+5.69%	+7.18%	-0.53%	+10.93%
SUPN Supernus Pharmaceuticals	-0.06%	+3.52%	-0.09%	+4.58%	+20.52%
TGTX TG Therapeutics	-1.57%	-0.32%	-3.24%	+1.01%	+80.88%
YMAB Y-mAbs Therapeutics	-3.54%	+1.28%	-11.56%	-9.73%	-62.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENDP Endo International	0.3017 of 5 stars	0.0	0.0	3.5	0.6	1.7	0.0
MDGL Madrigal Pharmaceuticals	4.2515 of 5 stars	3.4	1.0	4.6	2.7	3.3	0.6
SUPN Supernus Pharmaceuticals	1.5079 of 5 stars	1.2	1.0	4.1	2.6	0.0	0.0
TGTX TG Therapeutics	3.7912 of 5 stars	2.4	0.0	3.5	3.5	2.5	1.9
YMAB Y-mAbs Therapeutics	4.0131 of 5 stars	4.4	5.0	0.0	2.3	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENDP Endo International	0.00	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	2.89	Moderate Buy	$420.63	33.34% Upside
SUPN Supernus Pharmaceuticals	2.33	Hold	$36.00	8.70% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$43.80	18.12% Upside
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$15.60	257.80% Upside

Current Analyst Ratings Breakdown

Latest MDGL, YMAB, SUPN, TGTX, and ENDP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	TGTX TG Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$37.00
5/29/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $15.00
5/28/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00 ➝ $18.00
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/2/2025	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$441.00 ➝ $458.00
5/2/2025	MDGL Madrigal Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$422.00 ➝ $460.00
5/2/2025	MDGL Madrigal Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$394.00 ➝ $420.00
4/24/2025	MDGL Madrigal Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$443.00 ➝ $443.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENDP Endo International	$2.99B	0.00	N/A	0.06	($13.60) per share	0.00
MDGL Madrigal Pharmaceuticals	$180.13M	38.88	N/A	N/A	$34.59 per share	9.12
SUPN Supernus Pharmaceuticals	$661.82M	2.80	$4.17 per share	7.95	$18.76 per share	1.77
TGTX TG Therapeutics	$329M	17.89	$0.12 per share	314.02	$1.43 per share	25.93
YMAB Y-mAbs Therapeutics	$87.68M	2.25	N/A	N/A	$2.05 per share	2.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENDP Endo International	-$613.24M	-$11.07	N/A	0.00	N/A	-93.31%	-34.25%	6.72%	N/A
MDGL Madrigal Pharmaceuticals	-$465.89M	-$18.05	N/A	N/A	N/A	-123.38%	-50.54%	-37.19%	8/6/2025 (Estimated)
SUPN Supernus Pharmaceuticals	$73.86M	$1.11	29.84	23.00	N/A	9.27%	12.23%	9.17%	8/5/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	154.50	37.08	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.64	N/A	N/A	N/A	-31.84%	-30.59%	-22.70%	8/11/2025 (Estimated)

Latest MDGL, YMAB, SUPN, TGTX, and ENDP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	MDGL Madrigal Pharmaceuticals	-$3.64	N/A	N/A	N/A	$158.94 million	N/A
8/5/2025	Q2 2025	SUPN Supernus Pharmaceuticals	$0.47	N/A	N/A	N/A	$154.06 million	N/A
8/5/2025	Q2 2025	TGTX TG Therapeutics	$0.27	N/A	N/A	N/A	$147.76 million	N/A
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.62	-$3.32	+$0.30	-$3.32	$112.79 million	$137.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENDP Endo International	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SUPN Supernus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENDP Endo International	N/A	1.86	1.62
MDGL Madrigal Pharmaceuticals	0.17	5.91	5.58
SUPN Supernus Pharmaceuticals	N/A	2.44	2.26
TGTX TG Therapeutics	1.03	4.02	3.04
YMAB Y-mAbs Therapeutics	N/A	4.77	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENDP Endo International	80.39%
MDGL Madrigal Pharmaceuticals	98.50%
SUPN Supernus Pharmaceuticals	N/A
TGTX TG Therapeutics	58.58%
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ENDP Endo International	1.20%
MDGL Madrigal Pharmaceuticals	21.50%
SUPN Supernus Pharmaceuticals	8.80%
TGTX TG Therapeutics	10.64%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENDP Endo International	3,103	235.14 million	232.32 million	No Data
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable
SUPN Supernus Pharmaceuticals	580	55.99 million	51.06 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	36.36 million	Optionable

MDGL, YMAB, SUPN, TGTX, and ENDP Headlines

Recent News About These Companies

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of "Moderate Buy" from Brokerages

July 4, 2025 | americanbankingnews.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Moderate Buy" by Analysts

July 4, 2025 | marketbeat.com

YMAB Y-mAbs Therapeutics, Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Y mAbs Therapeutics News (YMAB) - Investing.com

June 26, 2025 | investing.com

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

June 11, 2025 | finance.yahoo.com

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

May 28, 2025 | globenewswire.com

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

May 26, 2025 | insidermonkey.com

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

May 26, 2025 | quiverquant.comQ

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

May 26, 2025 | globenewswire.com

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles

May 24, 2025 | investing.com

Truist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)

May 16, 2025 | theglobeandmail.com

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14, 2025 | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | finanznachrichten.de

Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

May 13, 2025 | globenewswire.com

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | globenewswire.com

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

May 7, 2025 | globenewswire.com

Why Y-mAbs Therapeutics, Inc.’s (YMAB) Stock Is Down 5.65%

May 6, 2025 | aaii.comA

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

May 6, 2025 | globenewswire.com

Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline

April 29, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDGL, YMAB, SUPN, TGTX, and ENDP Company Descriptions

Endo International NASDAQ:ENDP

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Madrigal Pharmaceuticals NASDAQ:MDGL

$315.46 +0.82 (+0.26%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$313.00 -2.46 (-0.78%)

As of 07/11/2025 05:25 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Supernus Pharmaceuticals NASDAQ:SUPN

$33.12 -0.02 (-0.06%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$33.13 +0.01 (+0.03%)

As of 07/11/2025 04:11 PM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

TG Therapeutics NASDAQ:TGTX

$37.08 -0.59 (-1.57%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$37.16 +0.08 (+0.22%)

As of 07/11/2025 07:54 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.36 -0.16 (-3.54%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$4.44 +0.09 (+1.95%)

As of 07/11/2025 06:27 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time